BPC-157 + TB-500 Quick Start
This is a single co-formulated blend of the two most commonly paired tissue-repair peptides — BPC-157 and TB-500 — at 10 mg each in one vial. It is supplied already reconstituted to 3 mL, so there is no mixing step. It is dosed as one product; the sections below break out how much of each component a given draw delivers.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
Blend Composition
Each pen vial contains 20 mg total across 3 mL, split evenly between the two components. Unlike GLOW, which is GHK-Cu-dominant at 5:1:1, this blend is a straight 1:1 pairing of the two repair peptides.
| Component | Vial content | Share of blend | Primary research focus |
|---|---|---|---|
| BPC-157 | 10 mg | 50% | Angiogenesis; tendon / gut / vessel repair |
| TB-500 | 10 mg | 50% | Actin regulation; cell migration, soft tissue |
Blend Dosing Protocol
This blend is supplied in a single format — a pre-reconstituted 3 mL pen vial — so there is one protocol rather than the separate injection, pen-vial and nasal-spray protocols used on the single-compound pages. Because the two components are fixed in one solution, the schedule follows the shorter-acting component, BPC-157, which is the daily-cadence peptide of the pair. Ranges are research-planning references, not personal dosing recommendations.
Pen Vial — Pre-Reconstituted 3 mL
| Band | Per dose (units) | Delivers | Frequency |
|---|---|---|---|
| Low | 5 units | 167 + 167 mcg | Once daily |
| Standard | 7.5 units | 250 + 250 mcg | Once daily |
| High | 10 units | 333 + 333 mcg | Once daily |
Cycle guidelines
| Approach | Duration | Review point | Best for |
|---|---|---|---|
| Standard | 4–6 weeks | Week 4 | General research planning |
| Extended | 6–8 weeks | Week 6 | Stubborn-injury research models |
Off periods of 2–4 weeks between cycles are common in research planning. As with the individual components, there is no published human cycling RCT, so these durations are conventions rather than validated regimens.
Per-Component Dosage Breakdown
Because the blend is 1:1, every draw delivers equal milligram amounts of both peptides. The table below compares what a standard 7.5-unit daily dose delivers against each compound's typical standalone range.
Standard band — 7.5 units (0.075 mL) once daily
| Component | Per dose | Weekly total | Typical standalone | Assessment |
|---|---|---|---|---|
| BPC-157 | 250 mcg | 1.75 mg | 250 mcg, 1–2× daily | In range |
| TB-500 | 250 mcg | 1.75 mg | 2–2.5 mg, 2× weekly loading | Maintenance-level |
Pen Use & Unit Math
This blend ships pre-reconstituted, so there is no bacteriostatic-water calculation to perform — the 3 mL fill is fixed at the point of manufacture. The only arithmetic that matters is converting a target dose into the units the pen dials in.
Pen Vial — 3 mL
| Component | Per unit | 7.5 u dose |
|---|---|---|
| BPC-157 | 33.3 mcg | 250 mcg |
| TB-500 | 33.3 mcg | 250 mcg |
Ships pre-reconstituted; no BAC water is added. 300 units per vial on the pen dial.
Lyophilized vial — 20 mg
| BAC | Per unit | 7.5 u dose |
|---|---|---|
| 3 mL | 33.3 + 33.3 mcg | 250 + 250 mcg |
| 2 mL | 50 + 50 mcg | 375 + 375 mcg |
Reconstitute to 3 mL to match every figure on this page. At 2 mL each unit carries 50 mcg of each peptide instead.
The unit formula
A 3 mL vial is 300 units on the pen dial, so each unit is 1/300th of the vial. For any component: per-unit mcg = total mg ÷ 300 × 1000. Here that is 10 ÷ 300 × 1000 = 33.3 mcg of each peptide per unit.
How to use the pen vial
- Inspect the vial. Confirm the label and the 10/10 mg strength. The solution should be clear and colorless.
- Never add water. A pen vial ships at its final 3 mL volume. Adding bacteriostatic water would dilute it and invalidate every unit figure on this page.
- Load the vial into the pen. Unscrew the pen's cartridge holder, seat the vial, and screw the holder back on until firm.
- Attach a fresh needle tip. Screw a new disposable pen needle onto the holder, then pull off the outer and inner caps. Use a new tip for every dose.
- Prime the pen. Dial 2 units, hold the pen needle-up, tap the holder so any air rises to the top, and press the button until a drop appears at the tip. Repeat until it does.
- Spin to the dose. Turn the dial to the unit figure from the table above — 7.5 units for the standard band. If you overshoot, spin back rather than pressing the button.
- Inject and hold. Press the button all the way down, then keep the needle in place for about ten seconds before withdrawing so the full dose is delivered.
- Remove and dispose of the needle. Unscrew the tip into a sharps container. Never store the pen with a needle attached — it lets solution leak out and air in.
- Cap and refrigerate. Store the pen with the vial still seated at 2–8 °C. Do not freeze.
Need the arithmetic for a different strength or fill volume? The reconstitution calculator works any vial size against any volume.
Why These Two Together
BPC-157 and TB-500 are paired because their reported mechanisms are complementary rather than overlapping. BPC-157 is studied mainly for angiogenesis — new blood-vessel formation via VEGFR2 and eNOS signaling — while TB-500 reproduces the actin-binding activity of Thymosin Beta-4, which is associated with cell migration into injured tissue. In simple terms, one line of research concerns building the blood supply and the other concerns moving repair cells in. Both remain preclinical findings.
BPC-157
Angiogenesis and gut/vessel repair signaling; short plasma half-life, hence daily cadence.
TB-500
Actin-mediated cell migration; longer-acting, hence its twice-weekly standalone schedule.
Convenience format
One vial, one draw, one refrigerated item instead of two separate reconstitutions.
Open question
No dedicated human trial exists for the combination; the rationale is entirely component-level.
Who Should Avoid This Blend
Both components carry the cautions listed on their individual pages, so the blend inherits all of them. Because human safety data is limited for each peptide, any eligibility decision should involve a licensed clinician.
Tested athletes
Both BPC-157 and TB-500 are on the WADA Prohibited List; use is an anti-doping rule violation.
Active or prior cancer
Angiogenic and pro-migratory pathways are a theoretical concern across both components, unresolved in humans.
Pregnancy & lactation
No published human reproductive or lactation safety data for either peptide.
Anyone seeking a treatment
These are research compounds, not medical treatments, and the blend is not an approved drug.
Side Effects & Safety
Combined profile
Reported effects reflect both components; review each component's page rather than treating the blend as a single new entity.
Injection-site reactions
Mild redness or small bumps are the most commonly reported short-term issue; rotate sites.
Theoretical proliferation risk
The repair pathways both peptides act on could in principle support unwanted cell growth; unresolved in humans.
Quality-control risk
A blend cannot be visually distinguished from a single-peptide solution — verify identity and per-component purity against a Certificate of Analysis.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| As supplied (liquid) | 2–8 °C | Ships reconstituted; refrigerate on arrival and do not freeze. |
| In use | 2–8 °C | Use within ~3–4 weeks of first puncture, as with any reconstituted peptide. |
| Appearance | Clear, colorless | Discard cloudy or particulate solutions. |
A pre-reconstituted format has no lyophilized shelf-stable state, so it does not have the −20 °C long-term storage option a powder vial does. Plan the cycle around the in-use window.
Blend vs Separate Vials
| Feature | BPC-157 / TB-500 blend | Two separate vials |
|---|---|---|
| Preparation | None — ships reconstituted | Two reconstitutions, two calculations |
| Dose independence | Fixed 1:1 — cannot vary one without the other | Each dosed on its own schedule |
| TB-500 loading phase | Not achievable at a daily BPC cadence | Full 2–2.5 mg, 2× weekly available |
| Injections | One draw daily | Daily BPC plus twice-weekly TB |
| Compared with GLOW | GLOW adds GHK-Cu and is GHK-dominant at 5:1:1; this blend is the straight repair pairing at 1:1. See GLOW. | |
Frequently Asked Questions
Is this two separate vials?
No. It is a single co-formulated blend — one pen vial holding 10 mg BPC-157 and 10 mg TB-500 in 3 mL, dosed as one product.
How much of each compound does a dose deliver?
Each U-100 unit carries 33.3 mcg of BPC-157 and 33.3 mcg of TB-500. A standard 7.5-unit daily dose therefore delivers 250 mcg of each. See the breakdown section for weekly totals.
Does it need reconstituting?
Depends on the format. The pen vial ships already reconstituted to 3 mL — adding water to it would invalidate every figure on this page. The lyophilized 20 mg vial does need reconstituting; use 3 mL to match these figures exactly.
Why is the TB-500 amount lower than its standalone dose?
The two peptides have different natural cadences. Dosed daily to suit BPC-157, the blend delivers about 1.75 mg of TB-500 per week — near TB-500's weekly maintenance total, but below its 4–5 mg/week loading total. Some researchers add standalone TB-500 during a loading phase.
How is this different from GLOW?
GLOW is a three-peptide blend that adds GHK-Cu and is GHK-dominant by weight at 5:1:1. This blend is the straight BPC-157 + TB-500 pairing at 1:1, with no cosmetic/collagen component.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
Formats & Sourcing
The protocol above is written against the format this blend is actually supplied in. It is offered as a pre-reconstituted pen vial and as a lyophilized 20 mg vial. Batch-specific Certificates of Analysis are issued per lot, covering both components; always verify the strength on the label before calculating anything.
| Format | Supplied as |
|---|---|
| Pen vial | Pre-reconstituted, 3 mL — BPC-157 10 mg + TB-500 10 mg |
| Lyophilized vial | 20 mg total powder (10 mg + 10 mg) — sold as the "Wolverine" blend |
Strengths and formats are listed as sold; confirm against the product page and the batch COA.
Reference material for this protocol, with batch COA:
View BPC-157 / TB-500 on Spyro Peptides →References
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des (2011).
- Hsieh MJ, et al. Pro-angiogenic BPC-157 and VEGFR2 activation. J Mol Med (2017).
- Goldstein AL, et al. Thymosin β4: actin-sequestering protein and tissue repair. Ann N Y Acad Sci (2012).
- Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol (1999).
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J (2025).
- World Anti-Doping Agency. Prohibited List 2025.
- Component-level dosing references compiled on the linked BPC-157 and TB-500 pages.